CompletedPhase 3NCT03828019

Adalimumab vs. Conventional Immunosuppression for Uveitis Trial

Studying Uveitis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: JHSPH Center for Clinical Trials
Principal Investigator: Douglas A Jabs, MD MBA
CCTand Evidence Synthesis, JHU, Bloomberg School of Public Health
Intervention: Adalimumab (ADA)(biological)
Enrollment: 227 target
Eligibility: 13 years · All sexes
Timeline: 2019 – 2024

Study locations (26)

Jules Stein Eye Institute, UCLA, Los Angeles, California, United States
University of California, San Francisco, San Francisco, California, United States
Anne Bates Leach Eye Hospital, University of Miami Miller School of Medicine, Miami, Florida, United States
Emory University, Atlanta, Georgia, United States
Northwestern University, Chicago, Illinois, United States
Rush University Medical Center, Chicago, Illinois, United States
University of Iowa, Iowa City, Iowa, United States
Johns Hopkins University, Baltimore, Maryland, United States
National Eye Institute, Bethesda, Maryland, United States
Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
University of Michigan Health System, Kellogg Eye Center, Ann Arbor, Michigan, United States
Washington University, St Louis, Missouri, United States
MidAtlantic Retina, Wills Eye Hospital, Philadelphia, Pennsylvania, United States
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Tennessee Retina, Nashville, Tennessee, United States
+11 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03828019 on ClinicalTrials.gov

Other trials for Uveitis

Additional recruiting or active studies for the same condition.

See all trials for Uveitis →

← Back to all trials